Clinical trial
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating…
NCT00070135 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00070135 |
|---|---|
| Title | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission |
| Official title | A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, Anti-Thymocyte Globulin, busulfan, fludarabine phosphate, methotrexate, tacrolimus, Allogeneic Hematopoietic Stem Cell Transplantation |
| Enrollment | 121 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2013 |
| Completion | Jun 15, 2016 |
| First posted | Oct 7, 2003 |
| Last update posted | Jun 12, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: